Sanofi India Limited
NSE: SANOFI · Pharmaceuticals
Snapshot
Unlock Sanofi India Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sanofi India Limited is a pharmaceutical company engaged in the manufacturing and trading of drugs across diverse therapeutic areas including diabetes, cardiology, and central nervous system disorders. The company operates as a subsidiary of Hoechst GmbH and distributes its portfolio of established brands through a network of independent distributors.
Business Model
The company generates revenue through the sale of pharmaceutical products and consumer healthcare brands, leveraging a robust distribution network to reach domestic and international markets. It focuses on high-demand therapeutic segments and maintains a portfolio of well-recognised brands such as Lantus, Clexane, and Allegra.
Growth Outlook
Growth is expected to be driven by the continued expansion of its core therapeutic franchises and the strategic management of its established brand portfolio. The company aims to leverage its global parent's R&D capabilities to maintain its competitive position in the Indian pharmaceutical market.
Key Risks
- Regulatory and Pricing Pressure. The company faces significant risks from government-mandated price controls on essential medicines which can impact profit margins.
- Supply Chain Disruptions. Dependence on global supply chains for active pharmaceutical ingredients exposes the company to potential logistical and geopolitical disruptions.
- Intense Market Competition. The Indian pharmaceutical sector is highly fragmented, leading to aggressive competition from both domestic generic manufacturers and multinational corporations.
- Intellectual Property Risks. The company may face challenges regarding patent protection and the entry of low-cost generic alternatives for its key branded products.
Start your research today
Unlock AI insights, financials, peers and live data on Sanofi India Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,805 Cr
TTM · standalone
NET PROFIT
₹324 Cr
TTM · standalone
EPS
₹140.59
TTM · standalone
RETURN ON EQUITY
40.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
52.8%
TTM · standalone
P/E
22.5x
Q1 FY27 · standalone
EV/EBITDA
13.8x
Q1 FY27 · standalone
EBITDA MARGIN
27.7%
TTM · standalone
NET PROFIT MARGIN
19.1%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sanofi India LimitedSANOFI | ₹7,274 Cr | 22.46 | 13.80 | -8.9% | 27.7% | 40.3% | 52.8% | -38.1% |
Aarti Pharmalabs LimitedAARTIPHARM | ₹7,786 Cr | 36.53 | 19.48 | 1.2% | 22.1% | 10.4% | 13.4% | -2.5% |
Bliss GVS PharmaBLISSGVS | ₹7,098 Cr | 54.87 | 29.75 | 14.5% | 25.6% | 12.0% | 16.9% | +329.5% |
Supriya Lifescience LimitedSUPRIYA | ₹6,864 Cr | 34.60 | 22.66 | 28.1% | 34.5% | 18.1% | 23.8% | +30.1% |
Innova Captab LimitedINNOVACAP | ₹6,726 Cr | 43.68 | 26.28 | 34.5% | 15.4% | 15.0% | 17.4% | +27.9% |
Senores Pharmaceuticals Ltd.SENORES | ₹6,578 Cr | 50.30 | 29.26 | — | 34.7% | 15.2% | 18.4% | +102.9% |
As of Q1 FY27
Financials
Sanofi India Limited
NSE: SANOFI · Pharmaceuticals
Snapshot
Unlock Sanofi India Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sanofi India Limited is a pharmaceutical company engaged in the manufacturing and trading of drugs across diverse therapeutic areas including diabetes, cardiology, and central nervous system disorders. The company operates as a subsidiary of Hoechst GmbH and distributes its portfolio of established brands through a network of independent distributors.
Business Model
The company generates revenue through the sale of pharmaceutical products and consumer healthcare brands, leveraging a robust distribution network to reach domestic and international markets. It focuses on high-demand therapeutic segments and maintains a portfolio of well-recognised brands such as Lantus, Clexane, and Allegra.
Growth Outlook
Growth is expected to be driven by the continued expansion of its core therapeutic franchises and the strategic management of its established brand portfolio. The company aims to leverage its global parent's R&D capabilities to maintain its competitive position in the Indian pharmaceutical market.
Key Risks
- Regulatory and Pricing Pressure. The company faces significant risks from government-mandated price controls on essential medicines which can impact profit margins.
- Supply Chain Disruptions. Dependence on global supply chains for active pharmaceutical ingredients exposes the company to potential logistical and geopolitical disruptions.
- Intense Market Competition. The Indian pharmaceutical sector is highly fragmented, leading to aggressive competition from both domestic generic manufacturers and multinational corporations.
- Intellectual Property Risks. The company may face challenges regarding patent protection and the entry of low-cost generic alternatives for its key branded products.
Start your research today
Unlock AI insights, financials, peers and live data on Sanofi India Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,805 Cr
TTM · standalone
NET PROFIT
₹324 Cr
TTM · standalone
EPS
₹140.59
TTM · standalone
RETURN ON EQUITY
40.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
52.8%
TTM · standalone
P/E
22.5x
Q1 FY27 · standalone
EV/EBITDA
13.8x
Q1 FY27 · standalone
EBITDA MARGIN
27.7%
TTM · standalone
NET PROFIT MARGIN
19.1%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27